Skip to content
2000
image of Comparative Study between Once Daily LABA-LAMA (Indacaterol- glycopyrronium) vs. Twice Daily LABA-AMA (Formoterol- glycopyrronium) in Stable COPD Patients Group B

Abstract

Background

An inflammatory lung condition that lasts a long time is called chronic obstructive pulmonary disease (COPD), it results from exposure to noxious substances, abnormalities in the bronchi, and obstruction of lung airflow owing to alveoli.

Objective

This study compares the safety and efficacy of LABA-LAMA combination therapy administered at varied frequencies to individuals with stable chronic obstructive pulmonary disease. The purpose of the study is to ascertain which of the two combinations performs better when considering both subjective and objective criteria.

Methods

Patients with Group B Stable COPD in the outpatient department were assigned into two random groups of 50 and given a different medication combination. Those in Group 1 received a single daily dose of Indacaterol + Glycopyrrolate, while those in Group 2 received two daily doses of Formoterol + Glycopyrrolate. Every four weeks, patients were checked on individually. Spirometric data (FEV1 (% Pred), Trough FEV1 (L), FEV1/FVC), and symptoms (cough, shortness of breath, sputum production, sleep disturbance) were recorded for each patient.

Results

After the therapy, both groups showed a decrease in symptomatic indicators. There was a notable improvement in trough FEV1 (L) and spirometric measurements. Moreover, no noticeable differences in subjective and objective criteria were observed between groups 1 and 2.

Conclusion

This study's conclusions are limited to patient populations with comparable features. To further elucidate the risk factors and potential genetic foundation of the disease conditions, more multi-centric studies including diverse ethnic groups must be conducted.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crmr/10.2174/011573398X352805250415083204
2025-05-07
2025-09-04

  • From This Site

    /content/journals/crmr/10.2174/011573398X352805250415083204
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Malerba M. Foci V. Patrucco F. Pochetti P. Nardin M. Pelaia C. Radaeli A. Single inhaler LABA/LAMA for COPD. Front. Pharmacol. 2019 10 390 390 10.3389/fphar.2019.00390 31105560
    [Google Scholar]
  2. Abdul Aziz M.I. Tan L.E. Wu D.B.C. Pearce F. Chua G.S.W. Lin L. Tan P.T. Ng K. Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 2018 13 3203 3231 10.2147/COPD.S173472 30349228
    [Google Scholar]
  3. Viniol C. Vogelmeier C.F. Exacerbations of COPD. Eur. Respir. Rev. 2018 27 147 170103 10.1183/16000617.0103‑2017 29540496
    [Google Scholar]
  4. Raluy-Callado M. Lambrelli D. MacLachlan S. Khalid J.M. Epidemiology, severity, and treatment of chronic obstructive pulmonary disease in the United Kingdom by GOLD 2013. Int. J. Chron. Obstruct. Pulmon. Dis. 2015 10 925 937 10.2147/COPD.S82064 25999708
    [Google Scholar]
  5. Quaderi S.A. Hurst J.R. The unmet global burden of COPD. Glob. Health. Epidemiol. Genom. 2018 3 e4 10.1017/gheg.2018.1 29868229
    [Google Scholar]
  6. Rogliani P. Calzetta L. Braido F. Cazzola M. Clini E. Pelaia G. Rossi A. Scichilone N. Di Marco F. LABA/LAMA fixed-dose combinations in patients with COPD: A systematic review. Int. J. Chron. Obstruct. Pulmon. Dis. 2018 13 3115 3130 10.2147/COPD.S170606 30323582
    [Google Scholar]
  7. Kornmann O. Dahl R. Centanni S. Dogra A. Owen R. Lassen C. Kramer B. Once-daily indacaterol versus twice-daily salmeterol for COPD: A placebo-controlled comparison. Eur. Respir. J. 2011 37 2 273 279 10.1183/09031936.00045810 20693243
    [Google Scholar]
  8. Maia I.S. Pincelli M.P. Leite V.F. Amadera J. Buehler A.M. Long-acting muscarinic antagonists vs. long-acting β 2 agonists in COPD exacerbations: A systematic review and meta-analysis. J. Bras. Pneumol. 2017 43 4 302 312 10.1590/s1806‑37562016000000287 28767773
    [Google Scholar]
  9. Horita N. Goto A. Shibata Y. Ota E. Nakashima K. Nagai K. Kaneko T. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Libr. 2017 2018 2 CD012066 10.1002/14651858.CD012066.pub2 28185242
    [Google Scholar]
  10. Schlueter M. Gonzalez-Rojas N. Baldwin M. Groenke L. Voss F. Reason T. Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: A systematic review and network meta-analysis. Ther. Adv. Respir. Dis. 2016 10 2 89 104 10.1177/1753465815624612 26746383
    [Google Scholar]
  11. Samp J.C. Joo M.J. Schumock G.T. Calip G.S. Pickard A.S. Lee T.A. Comparative effectiveness of long-acting beta 2 -agonist combined with a long-acting muscarinic antagonist or inhaled corticosteroid in chronic obstructive pulmonary disease. Pharmacotherapy 2017 37 4 447 455 10.1002/phar.1913 28226405
    [Google Scholar]
  12. Labor M. Braido F. Bikov A. Lahousse L. Rogliani P. Baiardini I. LABA/LAMA fixed dose combination in chronic obstructive pulmonary disease: The impact on health-related quality of life. Respiration 2018 96 4 370 381 10.1159/000491673 30227433
    [Google Scholar]
  13. To Y. Kinoshita M. Lee S.H. Hang Liang-Wen Ichinose Masakazu Fukuchi Yoshinosuke Kitawaki Tetsuji Okino Naoko Prasad Niyati Lawrence David Kramer Benjamin Assessing efficacy of indacaterol in moderate and severe COPD patients: A 12-week study in an Asian population. Respir Med. 2012 103 1715 10.1016/j.rmed.2012.09.002.
    [Google Scholar]
  14. Jadwiga A. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016 374 23 2222 10.1056/NEJMoa1516385.
    [Google Scholar]
  15. Sliwka A. Jankowski M. Gross-Sondej I. Storman M. Nowobilski R. Bala M.M. Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2018 8 8 CD012355 30141826
    [Google Scholar]
  16. Calzetta L. Rogliani P. Matera M.G. Cazzola M. A systematic review with meta-analysis of dual bronchodilation With LAMA/LABA for the treatment of stable COPD. Chest 2016 149 5 1181 1196 10.1016/j.chest.2016.02.646 26923629
    [Google Scholar]
  17. Suissa S. Dell’Aniello S. Ernst P. Comparative effectiveness and safety of LABA-LAMA vs. LABA-ICS treatment of COPD in real-world clinical practice. Chest 2019 155 6 1158 1165 10.1016/j.chest.2019.03.005 30922950
    [Google Scholar]
  18. Naline E. Trifilieff A. Fairhurst R.A. Advenier C. Molimard M. Effect of indacaterol, a novel long-acting β 2 -agonist, on isolated human bronchi. Eur. Respir. J. 2007 29 3 575 581 10.1183/09031936.00032806 17135231
    [Google Scholar]
/content/journals/crmr/10.2174/011573398X352805250415083204
Loading
Comparative Study between Once Daily LABA-LAMA (Indacaterol- glycopyrronium) vs. Twice Daily LABA-AMA (Formoterol- glycopyrronium) in Stable COPD Patients Group B
Bentham Science Publishers ; https://doi.org/10.2174/011573398X352805250415083204
/content/journals/crmr/10.2174/011573398X352805250415083204
/content/journals/crmr/10.2174/011573398X352805250415083204
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: sleep apnea ; Exacerbations ; dyspnea ; LABA ; LAMA, COPD

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test